{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "AUD", "exchange": "ASX", "shortName": "IMUGENE FPO", "longName": "Imugene Limited", "messageBoardId": "finmb_11113368", "market": "au_market", "marketState": "PRE", "earningsTimestamp": 1682679540, "earningsTimestampStart": 1682679540, "earningsTimestampEnd": 1682679540, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.01, "epsForward": -0.01, "sharesOutstanding": 6423040000, "bookValue": 0.032, "fiftyDayAverage": 0.1294, "fiftyDayAverageChange": -0.009400003, "fiftyDayAverageChangePercent": -0.07264299, "twoHundredDayAverage": 0.172325, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Australia/Sydney", "exchangeTimezoneShortName": "AEST", "gmtOffSetMilliseconds": 36000000, "esgPopulated": false, "regularMarketChangePercent": -4.000002, "regularMarketPrice": 0.12, "regularMarketChange": -0.0050000027, "regularMarketTime": 1683785404, "regularMarketDayHigh": 0.125, "regularMarketDayRange": "0.12 - 0.125", "regularMarketDayLow": 0.12, "regularMarketVolume": 6216261, "regularMarketPreviousClose": 0.125, "bid": 0.12, "ask": 0.125, "bidSize": 0, "askSize": 0, "fullExchangeName": "ASX", "financialCurrency": "AUD", "regularMarketOpen": 0.12, "averageDailyVolume3Month": 10394618, "averageDailyVolume10Day": 9144041, "fiftyTwoWeekLowChange": 0.004999995, "fiftyTwoWeekLowChangePercent": 0.043478217, "fiftyTwoWeekRange": "0.115 - 0.315", "fiftyTwoWeekHighChange": -0.195, "fiftyTwoWeekHighChangePercent": -0.6190476, "fiftyTwoWeekLow": 0.115, "fiftyTwoWeekHigh": 0.315, "twoHundredDayAverageChange": -0.052325003, "twoHundredDayAverageChangePercent": -0.30364138, "marketCap": 770764800, "forwardPE": -12.0, "priceToBook": 3.7499998, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "2.0 - Buy", "firstTradeDateMilliseconds": 915145200000, "priceHint": 4, "symbol": "IMU.AX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4-6 Bligh Street", "address2": "Suite 12.01 Level 12", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "website": "https://www.imugene.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 66, "title": "Exec. Chairman", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 350000, "fmt": "350k", "longFmt": "350,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Leslie  Chong", "title": "CEO, MD & Exec. Director", "fiscalYear": 2022, "totalPay": {"raw": 1066194, "fmt": "1.07M", "longFmt": "1,066,194"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2022, "totalPay": {"raw": 422977, "fmt": "422.98k", "longFmt": "422,977"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Monil  Shah M.B.A., Pharm.D.", "title": "Chief Bus. Officer", "fiscalYear": 2022, "totalPay": {"raw": 821742, "fmt": "821.74k", "longFmt": "821,742"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael  Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD", "age": 55, "title": "CFO & Company Sec.", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ursula  McCurry", "title": "Sr. VP of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Giovanni  Selvaggi", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}